Advanced Life Sciences granted FDA review for antibiotic
The FDA agreed to evaluate Advanced Life Sciences' cethromycin, a once-daily antibiotic that treats mild to moderate community-acquired pneumonia. The announcement comes after the company reported positive data from a late-stage trial that found cethromycin more effective than Abbott Laboratories' Biaxin. The agency plans to complete its review in 10 months.
CNNMoney.com | 12/03
This story published in FDLI SmartBrief on 12/04/2008
More from SmartBrief:
Abbott gets FDA approval for HIV test
Monday, September 21, 2009
Medtronic to pay $400M to settle stent dispute with Abbott
Tuesday, July 28, 2009
FDA clears Impax's 500-milligram generic Depakote
Thursday, August 6, 2009
Get stories like these delivered daily for FREE:
|
FDLI SmartBrief
Designed specifically for professionals involved in the food and drug industry, FDLI SmartBrief is a FREE daily e-mail newsletter. It provides the latest need-to-know news and industry information that maximizes your time, giving you an edge over your competition. Learn more |
|